Intellia Therapeutics - Stock Price History | NTLA

Historical daily share price chart and data for Intellia Therapeutics since 2021 adjusted for splits. The latest closing stock price for Intellia Therapeutics as of September 27, 2021 is 147.58.
  • The all-time high Intellia Therapeutics stock closing price was 176.78 on September 03, 2021.
  • The Intellia Therapeutics 52-week high stock price is 202.73, which is 37.4% above the current share price.
  • The Intellia Therapeutics 52-week low stock price is 18.81, which is 87.3% below the current share price.
  • The average Intellia Therapeutics stock price for the last 52 weeks is 82.49.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intellia Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 21.9922 14.5800 63.5300 9.4400 54.4000 270.82%
2019 15.1215 13.7000 18.5100 10.4300 14.6700 7.47%
2018 24.1216 21.5100 34.9500 11.3900 13.6500 -28.98%
2017 17.3448 13.4800 31.1200 11.3800 19.2200 46.61%
2016 19.4146 22.1000 29.5700 12.0200 13.1100 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.845B $0.058B
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29